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Abstract
Background: Influenza vaccine immunogenicity is diminished in patients living with HIV/AIDS. We evaluated the cost-
effectiveness and expected value of perfect information (EVPI) of three alternative influenza vaccine dosing strategies
intended to increase immunogenicity in those patients.
Methods: A randomized, multi-centered, controlled, vaccine trial was conducted at 12 CIHR Canadian HIV Trials Network
sites. Three dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine were used in HIV
infected adults: two standard doses over 28 days (Strategy A), two double doses over 28 days (Strategy B) and a single
standard dose of influenza vaccine (Strategy C), administered prior to the 2008 influenza season. The comparator in our
analysis was practice in the previous year, in which 82.8% of HIV/AIDS received standard-dose vaccination (Strategy D). A
Markov cohort model was developed to estimate the monthly probability of Influenza-like Illness (ILI) over one influenza
season. Costs and quality-adjusted life years, extrapolated to the lifetime of the hypothetical study cohorts, were estimated
in calculating incremental cost-effectiveness ratios (ICER) and EVPI in conducting further research.
Results: 298 patients with median CD4 of 470 cells/ml and 76% with viral load suppression were randomized. Strategy C was
the most cost-effective strategy for the overall trial population and for suppressed and unsuppressed individuals. Mean
ICERs for Strategy A for unsuppressed patients could also be considered cost-effective. The level of uncertainty regarding
the decision to implement strategy A versus C for unsuppressed individuals was high. The maximum acceptable cost of
reducing decision uncertainty in implementing strategy A for individuals with unsuppressed pVL was $418,000 - below the
cost of conducting a larger-scale trial.
Conclusion: Our results do not support a policy to implement increased antigen dose or booster dosing strategies with
seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine for individuals with HIV in Canada.
Trial Registration: ClinicalTrials.gov NCT00764998.
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Introduction
The likelihood of being clinically protected after influenza
vaccination is diminished in those living with HIV/AIDS [1].
Influenza symptoms are prolonged and the risks of complications
resulting from influenza infection are increased [2]. Furthermore,
the risk of influenza-related mortality is increased [2,3].
Current guidelines recommend that individuals with HIV/
AIDS receive the same standard influenza vaccination dosing
strategy as the general population (i.e. a single standard dose of
inactivated influenza vaccine administered annually in October/
November) [2,4]. This is supported by several studies and meta-
analyses suggesting reduced risk of influenza cases [5,6,7]. Higher
vaccine doses and/or booster dosing may maximize seroconver-
sion and seroprotection in individuals with HIV [1,8]. However,
few randomized studies of alternative dosing strategies have been
conducted to determine the optimal approach to achieving this
goal [1]. A recent randomized trial conducted in Canada during
the 2008 influenza season found that even with increased antigen
dose and booster dosing, non-adjuvanted influenza vaccine
immunogenicity is poor in HIV-infected individuals [9]. However,
there was a great deal of uncertainty regarding the level of clinical
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strata. As such, it is of interest to determine the cost-effectiveness of
the different strategies and to determine whether further research
to reduce the uncertainty in the decision to implement these
strategies is cost-effective.
We conducted a cost-effectiveness analysis utilizing data
generated from a randomized trial to determine the incremental
cost per quality-adjusted life year and expected value of perfect
information of conducting further research for three different
vaccine dosing strategies for people with HIV/AIDS.
Methods
Patient Population and Interventions
A randomized controlled trial assessing the immunogenicity
and efficacy of three influenza vaccine dosing strategies among
individuals with HIV was conducted in Canada during the 2008–
2009 influenza season (CTN-237). The vaccine used was the 2008
seasonal trivalent killed split non-adjuvanted influenza vaccine
(FluviralTM, GSK, Laval, Canada) containing A/Brisbane/59/
2007 (H1N1), A/Uruguay/716/2007 (H3N2), and B/Florida/4/
2006. The trial allocated patients randomly to three influenza
dosing strategies:
1. Strategy A (single standard dose+single standard dose booster):
15 mg dose of Fluarix H influenza vaccine on Day 0 and Day
28.
2. Strategy B (double dose+double dose booster): 30 mg dose of
Fluarix H influenza vaccine on Day 0 and Day 28.
3. Strategy C: (single standard dose+no booster): 15 mg dose of
Fluarix H influenza vaccine on Day 0 and placebo on Day 28.
Randomization was stratified by CD4 T lymphocyte count
(,200 cells/mL versus $200 cells/mL). Participants and all study
staff were blinded to allocation, except for the individual who
prepared the vaccine who had no direct contact with study
participants.
Hemagglutination inhibition (HAI) titres were measured at
Laval University (Dr Guy Boivin) according to WHO standard
protocol. Briefly, non-specific inhibitors were removed from
serum by overnight treatment with receptor destroying enzyme
(Denka Seiken, Tokyo, Japan). Physiologic saline solution was
then added to achieve a 1:10 dilution, followed by incubation
with packed guinea pig red blood cells (GRBC) (Lampire
Biological Laboratories Inc., Pipersville, PA) at 4 uC for 60 min
to remove non-specific agglutinins. Treated serum was serially
diluted in 25 ml of PBS and then mixed with an equal volume
of PBS containing 4 hemagglutinin units of A/Brisbane/59/
2007 (H1N1), A/Uruguay/716/2007 (H3N2) or B/Florida/4/
2006 viruses. After 30 min of incubation at room temperature,
50 ml of 1% GRBC solution was added to the mixture and
incubated for 45–60 min before evaluation of hemagglutina-
tion. The HAI titer was recorded as the reciprocal of the last
dilution that inhibited hemagglutination. These were measured
at baseline, week 4, week 8 and week 20. Further details on
serological testing and trial procedures can be found in Cooper
et al. [9].
Decision Analytic Model
This study was conducted from a societal perspective. Given
that influenza vaccination is required on an annual basis to
maintain protection against three different strains that mutate over
time (i.e. genetic drift) we considered a one-year vaccination
period, with costs and health-related quality of life outcomes
extrapolated beyond the one-year period to the lifetime of the
hypothetical cohorts.
We developed a Markov cohort model to track disease
progression through states of HIV plasma virological suppression
(#50 copies per ml), non-suppression (.50 copies per ml) and
death over one full influenza season. Each hypothetical cohort had
an equal mix of individuals who were virologically suppressed,
according to baseline trial figures. Costs and Health-related quality
of life outcomes of survivors were extrapolated beyond this 12-
month period for the estimated life expectancy of HIV/AIDS
patients at age 35 and residing in high-income countries [10].
Costs and QALYs were discounted at a rate of 3% per annum,
according to national and international guidelines for cost-
effectiveness analysis [11].
Transition probabilities between states were estimated from a
systematic review [12], the UK Collaborative HIV Cohort Study
[13], and the Antiretroviral Therapy Cohort Collaboration study
[10]. Using trial-based data, HAI titre levels were estimated for
each health state and each dosing strategy over the one-year time
horizon. We then estimated the probability of ILI in each health
state, using a mathematical relationship to solve for the rate of
clinical protection at each HAI titre level, and subsequently, the
probability of ILI. The decision-analytic model is illustrated in
Figure 1, while additional parameters required for the model are
presented in Table 1.
We calculated the incremental costs per quality-adjusted life
year gained for each of the three dosing strategies in comparison
to current practice, in which vaccine coverage was not complete.
82.8% of subjects recruited for this study reported being
vaccinated in the prior year. The comparator cohort, Strategy
D, for this study was therefore constructed from results of strategy
C (assumed standard single-dose vaccination) for 82.8% of the
cohort; estimates of mean HAI titre for patients in Strategy D
were calculated by weighting the mean HAI titre of patients in
Strategy C and HAI titre=10; the assumed HAI titre for non-
vaccination patients. The coverage percentage for general
population has been derived from the 2007 Canadian Commu-
nity Health Survey [14].
Estimating the probability of ILI. Previously, Dunning
et al. [15] proposed a scaled logistic model to estimate clinical
protection as a function of HAI titre. Nauta et al. [16] applied a
similar equation to determine the expectation of clinical protection
and demonstrated that the variance of HAI titre is also an
important determinant of clinical protection. We have expanded
this model to estimate the probability of contracting influenza for
each month by adding the exposure parameters for three strains of
the influenza virus.
The monthly probability of influenza for each strain (H1N1,
H3N2, or B) for our study population was a function of the HAI
titre level, which provides the expectation of clinical protection to
the influenza virus, and the probability that an individual with
HIV who was not clinically protected developing ILI due to
the virus. We described the methods used to calculate each
component below.
Clinical protection. For a given individual with HAI titre
measured at a given month, t=log2 (HAI titre/10) shows the log
transformed HAI titre. The clinical protection function is given by
p (t,a,b), which gives the relationship between t and the probability
of clinical protection from influenza.
Influenza Vaccines for Individuals with HIV/AIDS
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1
1zexp(azb:t)
ð1Þ
For a given rate of clinical protection at t=0 and threshold at
which clinical protection is equal to 50%, a and b can be derived
from Equation 1. We assumed a=6, which gave a protection rate
0.0025 for t=0, and an HAI titre threshold=40 as our base case
[17,18]. We also assumed that for a given group of individuals and
a given strain, t follows a normal distribution with mean m and
standard deviation s, consistent with prior studies [15,16]. We
then estimated the expectation of the probability of clinical
protection for a given population by:
p(CP)~
ð ?
{?
p(t,a,b):f(t,m,s)dt ð2Þ
Where f(t, m, s) is the normal density function of t with mean m and
standard deviation s, and p(CP) is the mean fraction of subjects
who are actually clinically protected [16]. It reflects the clinical
protection at the time of exposure to influenza virus among those
individuals with the mean of t equal to m and the standard
deviation of t equal to s. The integrals were solved numerically
using MATLAB 7.1 statistical toolbox.
Probability of contracting ILI. For each dosing strategy in
a given month, the mean probability of a population with given
distribution of HAI titre contracting a particular strain of influenza
can be expressed as follows:
P(ILI)~l(1{p(CP)) ð3Þ
In Equation 3, l is the probability that a susceptible individual
develops influenza. p(CP) is calculated from the data on HAI titre
of each group of individuals in our study as discussed above in
section 1 (Clinical protection). However, as we did not have any
data on l for our study population, we assumed that l is the same
for both general and HIV/AIDS population. The probability of
ILI was therefore calculated as:
P(ILI)~
PG(ILI)
1{pG(CP)
|(1{p(CP)), ð4Þ
Figure 1. Decision analytic model. All nodes following vaccine response are repeated each month throughout the initial 12 months of the model
duration; therefore patients not suffering fatal ILI or death due to other causes may transition from HIV viral load suppression to non-suppression,
and subsequently face differential risk of ILI at each month. The probability of ILI is summed across each of the three strains of influenza assessed in
CTN-237.
doi:10.1371/journal.pone.0027059.g001
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G(ILI) is the probability of contracting ILI for general
population and p
G(CP) is the mean fraction of subjects who are
clinically protected among the general population. P
G(ILI) at each
month is known by utilizing annual attack rate estimates from
peer-reviewed literature on the monthly distribution of ILI cases
form surveillance data [19]. p
G(CP) was derived from the literature
[20,21,22] and p (CP) is a function of HAI titre of our study
population and can be calculated from Equation 2. As a result,
P(ILI) for each strain can be calculated form Equation 4. The
mean probability of individuals with HIV/AIDS developing any
of the three types of influenza is then calculated as the sum of
strain-specific ILI probabilities at each month.
Literatureestimatesand surveillance datafrom the US Centrefor
Disease Control from 2002–2009 were used toestimate themonthly
attack rate of ILI for each strain in the following manner: First,
annual attack rates were derived from the literature [20,21].
Sentinel data on the percentage of physician visits due to ILI was
then used to derive the monthly distribution of the annual influenza
attack rate [19] (Figure 2). Finally, US virologic surveillance data
from lab reports was used to estimate the contribution of each three
strains (H1N1, H3N2, and B) to the total ILI cases in each month
[19]. We implicitly assumed that other influenza strains contributed
a negligible number of ILI cases.
Thus, using estimates of the annual influenza attack rate for the
general population [18,19], the monthly probability of ILI over
a typical influenza season [22,23] and seasonal distributions of
the particular strain of influenza [19], strain-and time-specific
probability of ILI were estimated. The overall probability of ILI
was then calculated as the sum of strain-specific ILI probabilities
for each month.
Estimating Mean HAI Titre Levels. In order to calculate
estimated HAI titre levels for each strain, dosing strategy and
Table 1. Model parameters.
Estimate Source
HIV disease progression
Probability of transition: HIV plasma viral load suppressed to unsuppressed* 80.7/1000PY [13]
Probability of transition: HIV plasma viral load unsuppressed to suppressed# 68/131 [12]
Probability of transition: mortality: [10]
CD4,25 38.4/1000PY
CD4 25–49 29.5/1000PY
CD4 50–99 26.4/1000PY
CD4 100–199 18.7/1000PY
CD4 200–349 10.9/1000PY
CD4$350 6.9/1000PY
Life Expectancy - years 32 (0.21) [10]
Annual HIV healthcare cost
CD4#50 $40,678 (95% CI: 33,566–47,789) [29]
CD4 51–200 $26,011 (95% CI: 23730,28292)
CD4 201–350 $19,565 (95% CI: 18,472, 20,658)
CD4 351–500 $16,859 (95% CI: 15,798, 17,920)
CD4.500 $16,614 (95% CI: 16,052 ,17,177)
Influenza-like Illness
ILI Attack rate: proportion of patients with ILI within 1 year 182/1000PY [20]
Vaccine coverage: General population 32% [14]
Vaccine coverage: HIV+ population [%] 241/291 [82.8%] CTN-237
Estimated HAI titre in general population**: [22]
Influenza Strain A H1N1 A H3N2 B
Week 0 15.0 (15.0) 22.4 (32.1) 52.5 (71.8)
Week 4 156.2 135.0) 324.3 (348.0) 232.6(127.0)
Week 20 50.3 (33.1) 84.6 (39.0) 64.0 (33.7)
Probability of mortality due to ILI event 9.9/1000 ILI cases [25]
HRQoL: Non-symptomatic patients*** 0.835 (0.01) CTN-237
HRQoL loss due to ILI 0.002 CTN-237
Estimated cost per ILI case## $672.76 (95% CI: 358.62, 1037.07) CTN-237, [30]
ILI: Influenza like illness; PY: Person-year; HRQoL: Health-related quality of life;
*Among pre-treated patients.
**Drawn from 2000/2001 estimates among a healthy elderly population [20].
#Unsuppressed patients were treated with one new drug; percentage of patients transitioning within a one-year period.
***Derived from baseline HUI3 scores of CTN-237 participants.
##In 2009$CDN. Included the costs of Derived from 5000 bootstrap re-samples of N=31 ILI events captured in the CTN-237 database.
doi:10.1371/journal.pone.0027059.t001
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determinants of HAI titre improvement through the 20-week trial
follow-up. As many trial participants did not show increases in
HAI titre levels, we estimated a hurdle model with the probability
of HAI titre improvement as the outcome in the first stage; and
t=log2 (HAI titre/10) the outcome among only those with
improvement in the second stage. HAI titre improvement was
defined as HAI titre ever being greater than 1:10 during follow-up.
This definition was data-driven, and defined as such to enable us
to make the most accurate predictions of ILI as a function of HAI
titre level. Covariates included virological suppression (#50 copies
per ml), time, and dosing strategy interactions.
Thus, for each strategy and health state, we estimated the
percentage of those with no HAI titre improvement and the
annual titre trajectory among those with HAI titre improvement.
For those with no improvement, t was assumed to remain equal to
zero throughout the year. Among those with improvement, mean t
and standard deviation at month 0 (weeks 0), month 1 (week 4),
month 2 (week 8), and month 5 (week 20) were estimated from the
trial data. The mean t for each strategy and health state was then
extrapolated to months 3 and 4 by assuming a linear trend in
mean titre between months 2 and 5, and extrapolated beyond the
5-month time horizon of the trial by assuming a linear trend in
mean t decline to zero at the end of the 12-month period. The
standard deviation at months 3 and 4, and beyond month 5 were
extrapolated by max (0.5, k*mean), where k=average (s0/m0, s1/
m1, s2/m2, s5/m5), m0, m1, m2, m5 and s0, s1, s2, s5 are the mean
of t and standard deviation at months 0, 1, 2, and 5, respectively.
The same methodology was applied to extrapolate HAI titre levels
for the general population for which HAI titre data was available
at weeks 0, 4 and 20 [22].
Estimating the probability of mortality due to
influenza. We assumed that the influenza case-fatality rate of
individuals with HIV/AIDS was equal to that of general
population [24]. An estimate of the probability of ILI-related
mortality for the general population was derived from the
literature [25].
Health-related quality of life. The health utilities index
(HUI-III), a valid and responsive measure of HRQoL for patients
with HIV/AIDS [26], was collected prospectively among patients
enrolled in this study at regular follow-up intervals. Additional
assessments were made during ILI events, and the duration
symptomatic ILI was reported to capture QALY loss due to ILI
events.
The temporary decline in health-related quality of life due to
ILI was estimated from the literature [27] given the low number of
ILI cases in our trial. Patients lost an average of 0.002 QALYs due
to ILI. QALYs were calculated for the duration of estimated life
expectancy at the baseline level of HRQoL observed in the trial.
Health-related quality of life outcomes were then extrapolated
to the lifetime of the patient cohort based on external estimates of
life expectancy for HIV/AIDS patients of similar clinical prognosis
[10].
Estimating the costs of ILI. Costs of influenza vaccines and
ILI, including inpatient care, outpatient care and foregone
productivity, were estimated from trial data. The human capital
Figure 2. Monthly distribution of the probability of ILI. Weekly influenza surveillance report form CDC [22]. 2008–2009 influenza season, week
39 ending October 3, 2009. Data shows only seasonal influenza and pandemic strain, 2009 influenza A (H1N1) virus, has been omitted.
doi:10.1371/journal.pone.0027059.g002
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among employed trial participants [28]. Costs were presented in
2009$CDN.
The lifetime costs of individuals with HIV/AIDS, sourced from
external estimates [29], were then applied to the surviving cohort
and discounted accordingly. Database analysis was conducted
using SAS version 9.2, while the probabilistic cohort simulation
model was constructed in Microsoft Excel.
Incremental Cost-Effectiveness Analysis
Incremental cost-effectiveness ratios (ICERs) were calculated as
the ratio of the difference in costs and the difference in the quality
adjusted life years (QALYs) gained between each of the tested
dosing strategies i and the current standard of care:
ICER~ Coststrategy iCostcurrent standard
  
=
QALYstrategy i{QALYcurrent standard
  
:
ð5Þ
Sensitivity Analysis
The deterministic results of our mathematical model were
subject to first- and second-order uncertainty, due to variability
in parameters, and the model structure [30]. Probabilistic
sensitivity analysis was conducted to identify the uncertainty
around ICERs and the subsequent decision rules generated from
the analysis.
Uncertainty around parameter estimates based on trial data was
quantified using non-parametric bootstrapping (5000 bootstrap re-
samples), while Monte Carlo simulation (5000 simulated values)
was used for parameters derived from external sources, in which
only measures of central tendency and variation were available.
95% credibility intervals (CI) were presented for each estimated
ICER.
Cost-effectiveness acceptability curves (CEACs), displaying the
probability that a given intervention is more cost-effective than the
alternative for a range of hypothetical maximum thresholds
regarding society’s willingness to pay for a single QALY.
Finally, one-way sensitivity analysis was conducted to determine
the sensitivity of our results to changes in specific model
parameters. In particular, we calculated ICERs (and 95% CI)
for model formulations in which the age at model entry was set at
25 and 45 years, and extreme values of the annual attack rate and
influenza case fatality rate.
Value of Information Analysis
Uncertainty surrounding the mean estimate of cost-effectiveness
can be costly if it increases the possibility of making the wrong
decision in terms of implementing or not implementing the health
intervention. The information gained from further research is
valuable, as it reduces the expected costs of this uncertainty [31].
The Expected Value of Perfect Information (EVPI) can be
interpreted as the expected costs of uncertainty, as perfect
information would eliminate completely the possibility of making
the wrong decision.
The EVPI is thus calculated as the difference between the
expected value of benefit of which the decision would be made
when the ‘‘true’’ parameter values were known (in other words,
with ‘perfect’ information), and the expected value of benefit of
which the decision would be made with uncertainty in all
parameter values (current information), as follows:
EVPI~Eh maxaBa(h,l){maxaEhBa(h,l) ð6Þ
Where Ba represents the net benefit of a given strategy ‘‘a’’ (in
monetary terms), which is a function of h, the uncertain
parameters, and l, the threshold cost-effectiveness ratio.
The EVPI represents the maximum sum that the health care
system should be willing to pay for reducing the uncertainty in the
decision to implement the vaccine dosing strategy in question.
Although the estimated EVPI is the expected maximum value for
additional information to inform the treatment of a single patient,
the information acquired can be used to treat all patients that may
benefit from the intervention in question. We can therefore
estimate the population, or total EVPI by multiplying the per-
person EVPI by the number of persons that may benefit from
intervention in a given year.
Results
Characteristics of the 298 patients recruited for this study were
presented in Table 2. Ninety percent were on HAART and 76%
had HIV plasma viral load levels below detection (#50 copies per
ml) at baseline (strategy A: 79%; strategy B: 72%; strategy C: 77%;
p=0.30). The median CD4 count was 470 cells/ml. 47% of these
patients were employed at the baseline assessment; the majority of
which employed full-time.
Trial-based estimates of the probability of HAI titre response
and estimated probability of ILI for each dosing strategy were
presented in Table 3 and Figure 3, respectively. The probability of
HAI titre response ranged from 0.55 (strategy A, unsuppressed,
H3N2) and 0.86 (Strategy C, suppressed, H3N2), and was higher
among patients with suppressed viral loads in all but 2 of 18
estimates. The estimated probabilities ILI among virologically
suppressed patients were similar in treatment strategies A through
Table 2. Patient characteristics.
N (%)/Mean (SD)
Age [mean (SD)] 46.8 (8.5)
Female [N (%)] 29 (9.7)
Ethnicity [N (%)]:
Caucasian 241 (80.9)
Black 21 (7.1)
Other 36 (12.1)
Employment [N (%)]:
Full-time 109 (36.6)
Part-time 31 (10.4)
Not employed 158 (53.0)
Virologically suppressed
[pVL#50 copies/ml] [N (%)]
227 (76.2)
CD4 cell count [mean (SD)]: Suppressed Unsuppressed
CD4 25–49 0 (0.0) 1 (1.4)
CD4 50–99 1 (0.4) 3 (4.2)
CD4 100–199 17 (7.5) 8 (11.3)
CD4 200–349 40 (17.6) 19 (26.8)
CD4$350 169 (74.5) 40 (56.3)
pVL=HIV plasma viral load.
doi:10.1371/journal.pone.0027059.t002
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treatment strategies B (double dose+double booster) and A (single
standard dose+single standard dose booster) had lower probabil-
ities of ILI than strategy C (single standard dose+no booster).
The cost of a single administration of influenza vaccine was
$17.45 ($8.25 for 15 mg of Fluarix [9,32] plus $9.20 administrative
cost [33]). Trial-based data was used to construct the costs of ILI
events. There were 31 distinct ILI events reported among 28
patients. While hospitalization was rare (N=1 (3.2%)), the
majority of patients sought outpatient care (71.0%), and missed
at least one day of work (61.3%). The estimated cost per ILI case
was $672.76 (95% CI: $358.62, $1,037.07). Costs of hospital
admission and inpatient care were derived from the St. Paul’s
Hospital Cost Model, which provides fully-allocated costs of all
activities in an urban Canadian tertiary care teaching hospital
[34].
Estimated costs, QALYs and ICERs for each dosing strategy in
comparison to strategy D (standard of care) in the baseline model
formulation were presented in Table 4. Strategy C (single standard
dose+no booster) dominated (lower costs, higher QALYs) strategy
D for the overall trial population. The ICER for strategy A (single
standard dose+single standard dose booster) was $104,781
($17,973, $2,939,656) per QALY gained in the overall trial
population, $68,190 ($132, $2,085,500) for unsuppressed patients,
and $122,152 ($19,307, Dominated) for virologically suppressed
patients. Mean ICERs for strategy B were well above commonly
used thresholds for the overall trial population, virologically
suppressed patients and unsuppressed patients. Credibility inter-
Figure 3. Mean of the probabilities of ILI and 95% credibility interval for each strategy by baseline pVL. Strategy A: single standard
dose+single standard dose booster; Strategy B: double dose+double dose booster; Strategy C: single standard dose+no booster; Strategy D: standard
of care.
doi:10.1371/journal.pone.0027059.g003
Table 3. Probability of HAI titre improvement*: results from 1
st-stage analysis.
Strategy A: single standard dose+single
standard dose booster N (%)
Strategy B: double dose+double dose
booster N (%)
Strategy C: single standard
dose+no booster N (%)
A H1N1 [Brisbane]
Baseline pVL#50 copies/ml 52 (71.23) 55 (74.32) 53 (76.81)
Baseline pVL.50 copies/ml 14 (63.64) 20 (76.92) 13 (65.00)
A H3N2 [Uruguay]
Baseline pVL#50 copies/ml 58 (79.45) 58 (78.38) 59 (85.51)
Baseline pVL.50 copies/ml 12 (54.55) 18 (69.23) 11 (55.00)
B [Florida]
Baseline pVL#50 copies/ml 54 (73.97) 55 (74.32) 52 (75.36)
Baseline pVL.50 copies/ml 14 (63.64) 22 (84.62) 12 (60.00)
*HAI Titre improvement was defined as HAI titre ever being greater than 1:10 during follow-up assessments.
doi:10.1371/journal.pone.0027059.t003
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lifetime QALYs gained between strategies, which were in the
order of 0.001.
Sensitivity analyses on several key model inputs were presented
in Table 5. ICERs were larger with lower ILI attack rates, and
more favourable with higher ILI attack rates. Results were
relatively insensitive to changes in the age of model entry. The
parameters for which we had no source specific to HIV/AIDS
clients were the probability of developing ILI among susceptible
individuals and the ILI case fatality rate. The estimate we’ve used
was derived from a general population sample, and thus may
underestimate the actual influenza case fatality rate for HIV/
AIDS clients. A higher ILI case fatality rate led to more favourable
ICERs indicating that Strategy A may be cost-effective for the trial
cohort, including individuals with suppressed plasma viral load.
Cost-effectiveness acceptability curves for each dosing strategy
were plotted for HIV virologically suppressed and unsuppressed
patients (Figure 4). Among suppressed patients, dosing strategy C
(single standard dose) was the most cost-effective strategy for a
wide range of threshold values of societal willingness to pay for a
single QALY. Among unsuppressed patients, strategy C was the
most cost-effective strategy for thresholds of up to $100,000; at a
threshold of $100,000, the probabilities of Strategies A and C
being the most cost-effective were nearly equal, however. Strategy
A was the most cost-effective for thresholds of $100,000–$330,000
per QALY, with strategy B becoming the most cost-effective
strategy at $330,000 per QALY gained.
Given the uncertainty surrounding mean ICER estimates for
individuals with unsuppressed plasma viral load in particular, we
calculated the EVPI of conducting further research to reduce
uncertainty in the decision rule to provide strategy A (single
dose+booster) versus strategy C (single dose) for this cohort. For a
threshold cost-effectiveness ratio of l=$100,000 per QALY and
an estimated annual prevalence of 15,600 HIV-positive individuals
with unsuppressed plasma viral load in Canada ((65,000
individuals with HIV in Canada [35])x(24% of patient within
study sample with unsuppressed plasma viral load – assumed to be
representative of population)=15,600), we found that the value of
further research is ($5.68 per individual * 15,600 individu-
als=$88,608) in the first year of implementation, and $417,973
over a 5-year timeframe.
Discussion
Using a novel modeling approach to determine the cost-
effectiveness of influenza dosing strategies incorporating individual
level data on HAI titre response, we found that ensuring standard,
single-dose inactivated, non-adjuvanted intramuscular influenza
vaccination for all HIV/AIDS patients is a cost-effective strategy.
Mean ICERs for the administration of a booster dose (strategy A:
single standard dose+single standard dose booster) for unsup-
pressed patients were within the range of commonly accepted
willingness to pay thresholds of $50,000–$100,000 [36]. While the
level of uncertainty regarding the decision to implement strategy A
versus C for unsuppressed patient was high, value of information
analysis found that the maximum acceptable cost of reducing
decision uncertainty in implementing strategy A for individuals
with unsuppressed pVL was $418,000 - likely below the expense of
conducting a larger-scale trial for this patient sub-group. The
results presented in this manuscript therefore do not support a
policy to implement this strategy on a national scale in Canada.
These conclusions are based on the best estimates of the model
parameters available. One-way sensitivity analyses revealed that
Strategy A (single standard dose+single standard dose booster)
may be cost-effective for unsuppressed individuals at or below age
25, in years of very high ILI attack rates, and with higher case
fatality rates than we used in our baseline analysis. These factors
should be considered in future policy decisions regarding influenza
vaccination among individuals with HIV/AIDS. Further, it is
plausible that our estimate on the rate of vaccination of HIV
patients in community settings is over-estimated. A report by Klein
et al. [37] suggested that only 78% of persons living with HIV who
presented to an HIV clinic with respiratory syndromes from 2003–
2006 were vaccinated with standard single dose influenza vaccine.
Decreasing the proportion of individuals vaccinated in the
comparator cohort (strategy D: standard of care) would act to
Table 4. Incremental costs per quality-adjusted life year gained: strategies A vs. Standard of Care.
ICER vs. Standard of care [2009$CDN]
Strategy A: Strategy B: Strategy C:
Standard of Care doses: 1+1 doses: 2+2 doses: 1+0
Trial cohort
Cost $412,201 ($393,647, $425,977) $412,215 ($393,665, $425,978) $412,249 ($393,701, $426,010) $412,198 ($393,645, $425,967)
QALY 17.72621 (16.99317, 18.26332) 17.72635 (16.99329, 18.26349) 17.72638 (16.99329, 18.26365) 17.72633 (16.99329, 18.26344)
ICER – $104,781 ($17,973, $2,939,656) $291,656 ($120,986, $2,211,232) D (D, $11,150)
Suppressed pVL
Cost $405,585 ($387,555, $419,332) $405,599 ($387,566, $419,344) $405,634 ($387,602, $419,384) $405,581 ($387,550, $419,322)
QALY 17.72818 (16.99568, 18.25104) 17.72830 (16.99581, 18.25110) 17.72831 (16.99585, 18.25112) 17.72832 (16.99580, 18.25111)
ICER – $122,152 (19,307, DT) $389,454 ($131,897, DT) D (D, $7,644)
Unsuppressed pVL
Cost $433,506.00 ($402,319,$462,553) $433,518.28 ($402,327, $462,557) $433,549.15 ($402,363, $462,586) $433,506.15 ($402,319,$462,552)
QALY 17.68808 (16.93064,18.21694) 17.68826 (16.93087,18.21716) 17.68836 (16.93087,18.21717) 17.68814 (16.93067,18.21610)
ICER – $68,190 ($132, $2,085,500) $156,609 ($63,922, $704,783) $2,722 (D, $63,943)
ICER=(Coststrategy i2Costcurrent standard)/(QALYstrategy i2QALYcurrent standard); D: Dominant - Lower cost, higher QALYs in comparison to usual care; DT: Dominated - higher
cost, lower QALYs in comparison to usual care. * Threshold for attaining 50% clinical protection for HIV/AIDS patients.
doi:10.1371/journal.pone.0027059.t004
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ordering of the alternative strategies would, however, remain
constant.
Given that this cost-effectiveness analysis was conducted
alongside a clinical trial, our analytic approach differs from those
typically applied in cost-effectiveness studies on vaccines. Kim and
Goldie [38] reported that some 90% of such studies published up
to 2005 were aggregate (population-level), deterministic models.
We created a closed, static and stochastic Markov cohort model,
taking advantage of individual-level data on an intermediate
outcome (HAI titre) used to determine the probability of clinical
protection against influenza. Dynamic simulation models have the
advantage of incorporating herd immunity in a population.
Because our study compared interventions in which all cohorts
were vaccinated and focused on a small subset of the population
which is potentially more vulnerable to the influenza epidemic, we
chose not to model herd immunity explicitly. We have
demonstrated that our modeling approach can be applied
successfully and should be considered for future cost-effectiveness
analyses of experimental vaccine strategies tested with randomized
controlled trial data.
A key factor in the modeling process was that the probability of
ILI was estimated from an intermediate outcome (HAI titre) rather
than from actual ILI cases. The total number of recorded ILI
events during the period of conduct of the study upon which this
analysis is based was low. As such, the trial was insufficiently
powered to detect differences in ILI rates between treatment arms.
As our analysis was intended to be generalizable across influenza
seasons with different attack rates, we chose to use external
estimates drawn from a wide time range.
Several limitations should be considered when interpreting our
analysis. The variation in estimated ILI rates was large, due to the
relatively small sample size of the study and heterogeneity in HAI
titre response profiles. However, we feel this novel strategy is an
important innovation in the study of influenza vaccine effective-
ness given the limited resources available for publicly-funded
clinical trials and the prevalence of use of HAI titres as outcomes
in such studies. The variation in outcomes was accounted for in
probabilistic sensitivity analysis, which verified the conclusions of
the deterministic analysis. Finally, we have not included the
potential administrative and marketing expenses that would be
required to ensure total vaccine coverage among individuals with
HIV/AIDS, nor the logistical requirements to execute a policy
providing differential care for suppressed and unsuppressed
individuals with HIV/AIDS. Not all methods of determining
influenza vaccine immunogenicity were considered in our analyses
[18,39,40]. Our analysis is based on influenza immunogenicity
achieved with inactivated, non-adjuvanted vaccine administered
Table 5. Results of one-way sensitivity analyses.
ICER vs. Strategy D: standard of care [2009$CDN]
Model Formulation Strategy A: Strategy B: Strategy C:
doses: 1+1 doses: 2+2 doses: 1+0
HAI Titre threshold*=80
Trial cohort $262,385 $534,570 $1,582
Suppressed pVL $327,568 $702,927 Dominant
Unsuppressed pVL $153,842 $294,590 $61,258
Influenza Attack Rate=10%
Trial cohort $231,392 $530,720 Dominant
Suppressed pVL $271,824 $702,238 Dominant
Unsuppressed pVL $152,685 $289,603 $31,936
Influenza Attack Rate=50%
Trial cohort $11,105 $71,064 Dominant
Suppressed pVL $18,872 $105,045 Dominant
Unsuppressed pVL Dominant $23,798 Dominant
Age of model entry=25
Trial cohort $99,288 $248,109 Dominant
Suppressed pVL $119,168 $333,112 Dominant
Unsuppressed pVL $60,803 $128,905 $803
Age of model entry=45
Trial cohort $122,278 $315,955 Dominant
Suppressed pVL $148,324 $426,855 Dominant
Unsuppressed pVL $71,744 $160,335 Dominant
Influenza Case Fatality Rate=0.1%
Trial cohort $70,733 $163,639 Dominant
Suppressed pVL $83,001 $216,580 Dominant
Unsuppressed pVL $47,171 $89,676 $9,708
*Threshold for attaining 50% clinical protection for individuals with HIV.
doi:10.1371/journal.pone.0027059.t005
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increased antigen dose and/or booster dosing strategies with live,
attenuated vaccines and with vaccines utilizing adjuvants. Low
representation of women and those with CD4 counts below 200
cells/ml may limit applicability of our findings to these
populations.
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